四川益生智同

Sichuan Yisheng Zhitong Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of next-generation cell therapies for solid tumors. Based in Chengdu, China, the company utilizes its proprietary Super CAR-T technology platform to engineer immune cells that can effectively penetrate and function within the immunosuppressive microenvironment of solid malignancies. Their lead pipeline candidates include YSZT-001, targeting Glypican-3 (GPC3) for hepatocellular carcinoma, and YSZT-002, targeting Claudin 18.2 for gastric cancer. By integrating advanced gene editing and cell engineering, Yisheng Zhitong aims to overcome the traditional limitations of CAR-T therapies in treating solid tumors. The company is strategically located in the Chengdu Tianfu International Bio-Town and has received support from regional venture capital. Their mission is to provide innovative and curative immunotherapy options for patients with high-incidence cancers.